(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Advaxis, Inc.
AO GENERIUM
Blueprint Medicines Corporation
Syndax Pharmaceuticals
Syndax Pharmaceuticals
Celldex Therapeutics